Post ASH speaker abstracts 2019

MDS & BONE MARROW FAILURE

 

Abstracts selected by Austin Kulasekararaj (King’s College Hospital) and Dominic Culligan (Aberdeen Royal Infirmary)

Abstract 1
The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Abstract (PDF)

 

Abstract 467
A Randomized Phase II Study of Azacitidine (AZA) Alone or with Lenalidomide (LEN), Valproic Acid (VPA) or Idarubicin (IDA) in Higher-Risk MDS: Gfm’s ‘pick a Winner’ Trial

Abstract (PDF)

 

Abstracts selected by Austin Kulasekararaj (King’s College Hospital)

Abstract 231
Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Abstract (PDF)

 

Abstract 465
A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS)

Abstract (PDF)

 

Abstract 463
Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive

Abstract (PDF)

 

Abstract 234
Safety and Efficacy, Including Event-Free Survival, of Deferasirox Versus Placebo in Iron-Overloaded Patients with Low- and Int-1-Risk Myelodysplastic Syndromes (MDS): Outcomes from the Randomized, Double-Blind Telesto Study

Abstract (PDF)

 

Abstract 229
Eltrombopag Improves Hematopoiesis in Patients with Low to Intermediate-2 Risk Myelodysplastic Syndrome (MDS)

Abstract (PDF)

 

Abstract 3091
Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Abstract (PDF)

 

Abstract 1818
Results of a Phase 2 Trial of the Monocyte-Targeted Histone Deacetylase Inhibitor Tefinostat (CHR-2845) in Chronic Myelomonocytic Leukemia (CMML) — the UK Monocle Study

Abstract (PDF)

 

Abstract 1821
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML)

Abstract (PDF)

 

Abstract 1823
Androgen Therapy for Lower-Risk Myelodysplastic Syndrome

Abstract (PDF)

 

Abstract 4375
Danazol Treatment for Thrombocytopenia in Lower-Risk Myelodysplastic Syndromes: A Pilot Real Life Experience

Abstract (PDF)

 

Abstract 3092
Forty Percent of MDS Patients Wish They Received Red Blood Cell Transfusions at Higher Hemoglobin Thresholds Than They Currently Are: A Multinational Transfusion Audit

Abstract (PDF)

 

Abstract 971
Maintenance with 5-Azacytidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Abstract (PDF)

 

Abstracts selected by Dominic Culligan (Aberdeen Royal Infirmary)

Abstract 243
Safety and Efficacy, Including Event-Free Survival, of Deferasirox Versus Placebo in Iron-Overloaded Patients with Low- and Int-1-Risk Myelodysplastic Syndromes (MDS): Outcomes from the Randomized, Double-Blind Telesto Study

Abstract (PDF)

 

Abstract 527
A Feasibility Randomized Trial of Red Cell Transfusion Thresholds in Myelodysplasia

Abstract (PDF)

 

Abstract 750
Clinical Relevance of Clonal Hematopoiesis in the Oldest-Old Population: Analysis of the “Health and Anemia” Study

Abstract (PDF)